4.6 Article

Hereditary Gastric Cancer: Single-Gene or Multigene Panel Testing? A Mono-Institutional Experience

期刊

GENES
卷 14, 期 5, 页码 -

出版社

MDPI
DOI: 10.3390/genes14051077

关键词

gastric cancer; multigene panel testing; BRCA1; BRCA2; CDH1; MSH2; hereditary diffuse gastric cancer syndrome; homologous recombination DNA repair genes

向作者/读者索取更多资源

Gastric cancer has traditionally been overlooked in hereditary cancer research, but the advent of multigene panel testing has shed light on the involvement of additional genes, particularly those related to homologous recombination repair. Our study identified CDH1 and MSH2 as genes associated with early-onset diffuse and later-onset intestinal gastric cancers, respectively. Multigene panel testing was found to be advantageous in patients with unspecific phenotypes, although it posed challenges in result interpretation.
Gastric cancer (GC) has long been a 'Cinderella' among hereditary cancers. Until recently, single-gene testing (SGT) was the only approach to identify high-risk individuals. With the spread of multigene panel testing (MGPT), a debate arose on the involvement of other genes, particularly those pertaining to homologous recombination (HR) repair. We report our mono-institutional experience in genetic counseling and SGT for 54 GC patients, with the detection of nine pathogenic variants (PVs) (9/54:16.7%). Seven out of fifty (14%) patients who underwent SGT for unknown mutations were carriers of a PV in CDH1 (n = 3), BRCA2 (n = 2), BRCA1 (n = 1), and MSH2 (n = 1), while one patient (2%) carried two variants of unknown significance (VUSs). CDH1 and MSH2 emerged as genes involved in early-onset diffuse and later-onset intestinal GCs, respectively. We additionally conducted MGPT on 37 patients, identifying five PVs (13.5%), including three (3/5:60%) in an HR gene (BRCA2, ATM, RAD51D) and at least one VUS in 13 patients (35.1%). Comparing PV carriers and non-carriers, we observed a statistically significant difference in PVs between patients with and without family history of GC (p-value: 0.045) or Lynch-related tumors (p-value: 0.036). Genetic counseling remains central to GC risk assessment. MGPT appeared advantageous in patients with unspecific phenotypes, although it led to challenging results.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据